Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022
Castle Biosciences (CSTL) will announce its fourth quarter and full year 2021 financial results on February 28, 2022, after market close. A conference call and webcast will follow at 4:30 PM ET the same day, providing an opportunity for management to discuss the results and engage in a Q&A session. Investors can access the live event via phone or through the Company’s website. This release highlights the company's dedication to innovative diagnostics aimed at improving patient outcomes.
- Castle Biosciences focuses on transforming disease management through innovative diagnostics.
- The company has a portfolio of tests targeting high clinical needs in skin cancer.
- Ongoing research and development for tests in other conditions shows commitment to growth.
- None.
Company management will host a conference call and webcast to discuss its financial results at
Conference Call and Webcast Details
A live webcast of the conference call can be accessed here: https://event.on24.com/wcc/r/3574576/969E1FF81B791B8705198534F60A01D4 or via the webcast link on the Investor Relations page of the Company’s website, https://ir.castlebiosciences.com/overview/default.aspx. Please access the webcast at least 10 minutes before the conference call start time. An archive of the webcast will be available on the Company’s website until
To access the live conference call via phone, please dial 1 844 200 6205 from
There will be a brief Question & Answer session following management commentary.
About
Castle’s current portfolio consists of tests for skin cancers, uveal melanoma and Barrett’s esophagus. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq and TissueCypher are trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20220214005121/en/
Investor Contact:
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source:
FAQ
When will Castle Biosciences announce their fourth quarter and full year 2021 financial results?
What time is the Castle Biosciences conference call on February 28, 2022?
How can I access the Castle Biosciences conference call?